In dogs, PD-L1 expression is reported in various tumour types including malignant melanoma, osteosarcoma, hemangiosarcoma, transitional cell carcinoma, nasal adenocarcinoma, and B-cell lymphoma [21,24–30], suggesting that these tumour types are potential target for canine ICI therapies. This evidence concerns the gene CD274 and neoplasm.